SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as retail and institutional investors capitalize on a high-velocity short squeeze fueled by massive short interest and intense anticipation of pivotal REGAL trial data. The community is actively debating the significance of the trial's longevity, the potential for a transformative buyout, and the impact of the drug's novel immunological design, while monitoring a rapid surge in volume that continues to pressure heavily shorted positions.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors rotate into the stock as a defensive safe haven amid broader market volatility, with community interest amplified by its aggressive expansion into the streaming advertising space through the Vibe.co acquisition. While the stock has faced near-term pressure from concerns over consumer spending and insider selling, many are focused on its core supply chain efficiency and potential for sustained growth.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing significant market momentum driven by a strong quarterly earnings beat and a substantial $1.2 billion backlog, despite investor tension regarding lower-than-expected forward guidance. Community sentiment remains split between excitement over the company's critical role in drone defense technology and concerns about valuation, margin pressure, and the impact of the BlueHalo integration on near-term profitability.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the market reacts to the announcement of an upcoming FDA Advisory Committee meeting for its DMD therapy, deramiocel, sparking debate over whether this represents a routine regulatory step or an additional hurdle. While the community remains divided over the implications of the meeting, many investors are focused on the company's recent positive long-term clinical data and are using the temporary price volatility as an opportunity to accumulate shares ahead of the potential August approval.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is experiencing significant market volatility as investors weigh the company's decision to divest Del Taco against intense short-interest concerns. The community remains deeply divided, with bulls pointing to potential turnaround plays and short-squeeze opportunities, while bears express significant skepticism regarding the company's debt levels and long-term viability.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining investor attention following a strategic decision to discontinue internal discovery programs and close its Alabama research facility, a move aimed at prioritizing external innovation and increasing long-term capital efficiency. Community discourse is heavily focused on the potential that these operational adjustments are a deliberate step to streamline the company for a future buyout, amid ongoing speculation regarding the value of its HAE portfolio.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp. is experiencing significant market interest driven by its critical role in the semiconductor AI infrastructure buildout, with recent analyst upgrades reflecting a durable, long-term industry upcycle. Community discourse remains highly active, with traders closely monitoring its technical performance and potential for continued volatility as the stock hits new valuation benchmarks.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing intense investor focus as the stock navigates a pivotal commercial phase marked by robust revenue guidance, expanded dialysis adoption, and ongoing institutional efforts to secure favorable reimbursement legislation like K-CAPA. Community sentiment remains sharply divided, with longs highlighting the company's strong cash position and pipeline expansion, while vocal bears express frustration over price volatility and the ongoing transition from transitional add-on payments.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is capturing significant market attention as traders weigh a major ICE procurement contract against heavy insider selling and broader sector volatility. The community remains deeply divided, with bulls pointing to the company's dominant public safety ecosystem and AI growth, while skeptics focus on high valuation multiples and recent downward price pressure.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as investors aggressively rotate into physical AI and robotics infrastructure, bolstered by a strategic production deal for its new high-resolution REV8 sensors. The community is actively discussing Ouster's role as a critical perception layer in the broader robotics supply chain, with many highlighting its potential for long-term growth as autonomous systems move from laboratory development to industrial-scale deployment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Davis Fundamental ETF Trust - Davis Select Worldwide ETF

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

DWLDDavis Selected Advisers L.P - Davis Select Worldwide ETF

Latest DWLD News